Momotaro-Gene, an Okayama-based venture company, has developed a novel cancer therapy based on REIC, a tumor suppressor gene, which proved promising in a US-Japan phase I study during treatment of prostate cancer and malignant mesothelioma. The new capital comes from DCI partners, a Japanese biotech startup fund.
Momotaro Gene news release, March 15, 2017
Momotaro-Gene Inc. raises 1.1 billion Yen venture capital for phase II studies in the US